L. V. Grebinyk

L. V. Grebinyk

Auto-generated profile, based on publicly available information

L. V. Grebinyk

Державна установа «Інститут медичної радіології та онкології ім. С.П. Григорʼєва Національної академії медичних наук України», Харків, Україна

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2024 in Український радіологічний та онкологічний журнал
Verified
Journal Article
Open access
OBO.M. Bilyy
O.M. Bilyy
NMN.A. Mitrіaіeva
N.A. Mitrіaіeva
MKM.V. Krasnoselskyi
M.V. Krasnoselskyi
LGL.V. Grebinyk
L.V. Grebinyk
Background. One of the most prominent features of secondary edematous breast cancer (SEBC), which is the most malignant form of this type of cancer, is severity of chronic inflammation that is important for pathogenesis and progression of the disease. As of now, there is evidence of association of carcinogenesis and inflammation. The transcription factor (NF-kB) and pro-inflammatory cytokines play a pivotal role in both inflammation and carcinogenesis. The regulation of NF-kB signal pathways is impaired in a lot of malignant diseases, including breast cancer (BC). Thus, the study of the content of pro-inflammatory cytokines and NF-kB is of high priority, as it can provide valuable information about the course of the tumor process. However, there are few research papers that deal with association of cytokine profile and NF-kB in breast tumors. Purpose – is to study the content of NF-kB-р105 and pro-inflammatory cytokines (IL-6, IL-8, TNFα) in the blood serum of patients with secondary edematous breast cancer. Materials and Methods. 87 patients (42 with SEBC, 45 with BC) were examined prior to treatment. The age of 42 patients with T4bN0-3M0 SEBC ranged from 34 to 71 years (median 53.1). The ductal cancer was found in 30 patients (71.43%), the lobular cancer – in 12 patients (28.57%). The tumor of more than 5 cm was detected in 20 individuals (47.6%), the tumor of less than 5 cm – in 22 individuals (52.4%). The comparison group consisted of 45 patients with BC, with their age ranging from 30 to 67 years (median 52.3). They had T3-4N1-3M0 non-edematous locally advanced BC. The tumor of more than 5 cm was detected in 12 patients (26.7%), the tumor of less than 5 cm – in 33 patients (73.3%). The ductal cancer was diagnosed in 33 patients (73.3%), the lobular cancer – in 12 patients (26.7%). The control group consisted of 10 patients with fibroadenomas. The content of cytokines (IL-1B, IL-2, IL-6, IL-8, TNFα) in the blood serum of patients was measured using the ELISA assay and CJSC «Vektor-Best» standard assay kits. The content of NF-kB1 subunit (р105 → р50) was measured using the ELISA assay and the Human NFkB – p105 (Nuclear factor NF-kappa-B p 105 subunit) ELISA Kit. The measurement was performed using the Immunochem-2100 American semi-automatic immunoassay analyzer. Results. It was found that in SEBC, the levels of pro-inflammatory cytokines IL-6, IL-8, TNFα were increased by 1.4 times, compared to the parameters in BC, and the level of IL-8 was the highest. The total level of NF-kB increased by 14,7 times in patients with SEBC and by 2,4 times in patients with BC, compared to individuals with fibroadenomas. The level of NF-kB in SEBC in groups with IL-6, TNFα was higher than in groups with BC by 3.1 and 1,7 times, respectively. It was found that the highest level of NF-kB was in the group with cytokine IL-8. In SEBC, it was higher by 5.7 times than in BC. In patients with SEBC, correlations between NF-kB and cytokines were established: NF-kB and IL-8 (r = 0.80; p < 0.05); NF-kB and IL-6 (r = 0.60; p < 0.05); NF-kB and TNFα (r = 0.60; p < 0.05). Thus, one feature of SEBC is the increase in the content of NF-kB, IL-6, and TNFα, and also a significant increase in the level of NF-kB and IL-8, compared to the parameters in patients with BC as well as in patients with fibroadenomas. Conclusions. It was found that there was activation of the transcription factor NF-kB-p105 and a significant increase in the levels of pro-inflammatory cytokines (IL-6, IL-8, TNFα) in the blood serum of patients with SEBC, compared to patients with fibroadenomas, which indicates high carcinogenic potential of the tumor and the presence of the inflammatory component. It was demonstrated that the highest level of NF-kB-p105 was detected in the group of patients with SEBC with the highest level of cytokines IL-8. It was also found that in patients with SEBC, the level of the transcription factor and pro-inflammatory cytokines IL-6, IL-8, TNFα in the blood serum was significantly higher than in patients with BC, thereby confirming severe aggressiveness of this form of the disease.

3 December 2024 in Український радіологічний та онкологічний журнал
Verified
Journal Article
Open access
PDF file
OBO.M. Bilyy
O.M. Bilyy
NMN.A. Mitriaieva
N.A. Mitriaieva
LGL.V. Grebinyk
L.V. Grebinyk
SAS.V. Artiukh
S.V. Artiukh
Background. The transcription factor NF-kB plays a pivotal role in various physiological processes, such as immune response, cell proliferation, apoptosis, and inflammation. It controls the transcriptional activity of numerous genes responsible for various pathways of inflammatory and oncological processes. Of particular interest are the signaling pathways regulated by NF-kB in carcinogenesis, angiogenesis, and tumor resistance to chemo- and radiotherapy. The interplay between oncological and inflammatory processes, accompanied by constitutive NF-kB activation, makes it a promising target for directed pharmacological intervention in cancer therapy. Purpose – to analyze current perspectives on the role of the transcription factor NF-kB in carcinogenesis, inflammation, and chemo- and radiotherapy resistance of tumors, and to assess its specific features in patients with secondary edematous breast cancer (SEBC). Materials and methods. The study presents data from our own research on 87 patients (42 with T4bN0-3M0 secondary edematous breast cancer (SEBC) and 45 with T3N0-3M0 breast cancer (BC)) aged 34–71 years (median 53.1) who were treated at the State Organization «Grigoriev Institute for Medical Radiology and Oncology of the National Academy of Medical Sciences of Ukraine». The control group consisted of 10 patients with fibroadenomas. The levels of IL-1B, IL-2, IL-6, IL-8, and TNF-α were measured using ELISA with «Vector-Best» kits in the serum of these patients. The content of NF-kB1 (p105 → p50) was also measured using ELISA with the «Human NF-kB – p105 ELISA Kit» and the «Immunochem-2100» analyzer (USA). Results. Based on literature data and our own research, NF-kB plays a key role in the functioning of many cancer cells through its activation and disruption of NF-kB signaling pathways. The NF-kB level was 9.8 times higher in patients with BC and 27.4 times higher in patients with SEBC than in patients from the control group with benign tumors. It was demonstrated that NF-kB plays a critical role in chronic inflammation, driving the link between inflammation and cancer by inducing proinflammatory cytokines such as IL-6, TNF-α, chemokine IL-8, and the COX-2 enzyme. The NF-kB level in the SEBC patient group with IL-6 and the group with TNF-α was 3.1 and 2.3 times higher than in patients of the respective BC groups. The highest level was found in the IL-8 group, where it was 5.7 times higher than in BC patients. Correlation analysis in SEBC patients revealed a significant relationship between NF-kB and IL-8 (r = 0.80; p < 0.05) and a less significant relationship between NF-kB and IL-6 (r = 0.60; p < 0.05), and between NF-kB and TNF-α (r = 0.60; p < 0.05). It was confirmed that NF-kB and the protein system associated with it, which is linked with the inflammatory cascade, control malignant transformation and its prevention. The possibility of targeting NF-kB for cancer treatment is being explored. Inhibition of the NF-kB activity can be achieved by influencing any of its activation stages. NF-kB serves as a marker for prediction and development of tumor resistance to radiation therapy in cancer patients, as well as a marker for developing NF-kB inhibition drugs. Conclusions. The analysis of literature data and our own research showed that activation of the transcription factor NF-kB plays a significant role in carcinogenesis and inflammation, and causes tumor chemoradioresistance. In SEBC, the highest NF-kB-p105 level was observed in the group with the highest IL-8 content. It was demonstrated that in SEBC patients, serum levels of NF-kB-p105, IL-6, IL-8, and TNF-α were significantly higher than in BC patients. These data indicate the highly aggressive nature of SEBC. NF-kB activity can be modulated using inhibitors that either target its activation pathways or directly block it. NF-kB, along with its role in the link between cancer and inflammation, can serve as a therapeutic target for suppressing tumor growth and sensitizing cancer cells to established cytotoxic anti-cancer therapy.

31 October 2025 in The Journal of V. N. Karazin Kharkiv National University, Series "Medicine"
Verified
Journal Article
Closed access
OBO.M. Bilyі
O.M. Bilyі
NMN.A. Mitrіaіeva
N.A. Mitrіaіeva
LGL.V. Grebinyk
L.V. Grebinyk
OSO.V. Slobodianiuk
O.V. Slobodianiuk
SPS.O. Pylypenko
S.O. Pylypenko
Background. Secondary-edematous breast cancer is characterized by high aggressiveness and a lack of clear prognostic markers. Studying the role of Vascular Endothelial Growth Factor in relation to the expression of steroid hormone receptors, HER2/neu, and Ki-67 in tumors allows assessment of the tumorʼs aggressiveness and helps optimize treatment. Purpose – to investigate the relationship between serum Vascular Endothelial Growth Factor levels and the expression of molecular markers in tumors of secondary- edematous breast cancer patients during treatment dynamics, and to determine the prognostic factors of the disease course. Materials and Methods. Fifty-four Secondary Estrogen Receptor–Positive Breast Cancer patients with T4bN0-2M0 were examined and underwent comprehensive treatment: neoadjuvant polychemotherapy (AC×4-D×4 or AC×4-P×12), surgical intervention, and radiation therapy. Vascular Endothelial Growth Factor levels in serum were determined before and after treatment by enzyme-linked immunosorbent assay, and ER, PR, HER2/ neu, and Ki-67 expression in the tumor was determined immunohistochemically. Results. A significantly increased serum Vascular Endothelial Growth Factor level was found in secondary-edematous breast cancer patients compared to the control group. Elevated Vascular Endothelial Growth Factor correlated with a higher tumor grade, Ki-67 overexpression, negative steroid hormone receptor status, and Human Epidermal Growth Factor Receptor 2. After treatment, Vascular Endothelial Growth Factor levels decreased in patients with tumor regression, while in those with disease progression, VEGF remained consistently high. Conclusions. Serum Vascular Endothelial Growth Factor is an important marker of tumor aggressiveness and treatment response in secondary-edematous breast cancer. Monitoring Vascular Endothelial Growth Factor alongside tumor molecular markers can be used to predict disease progression and select treatment strategies.

12 December 2022 in Український радіологічний та онкологічний журнал
Verified
Journal Article
Open access
PDF file
NMN. A. Mitrіaіeva
N. A. Mitrіaіeva
LGL. V. Grebinyk
L. V. Grebinyk
NBN. V. Bilozor
N. V. Bilozor
VSV. P. Starenkyі
V. P. Starenkyі
Background. Overcoming radioresistance is an important problem in radiation oncology. Therefore, the development of new approaches to modeling the radiosensitivity of tumors in cancer patients becomes relevant and important. Cyclooxygenase-2 (COX-2) inhibitors are new agents for radiomodification in various radiation therapy schemes, the use of which slows down angiogenesis by suppressing the activity of the COX-2 enzyme. Purpose. To determine the content of indicators of radioresistance: vascular endothelial growth factor (VEGF), COX-2, prostaglandin E-2 (PGE-2) in the blood serum of patients with non-small cell lung cancer (NSCLC) and changes in their levels with different schemes of radiation therapy (RT). Materials and methods. 36 patients with NSCLC were examined and treated, who were divided into four groups: RT (the first group – 16 patients), RT with the COX-2 inhibitor – ranselex (the second group – 9 patients), RT with ranselex and cisplatin (the third group – 5 patients ) and RT with cisplatin (fourth group – 6 patients). The patients received a course of radiation treatment using a Clinac 600C linear accelerator. The classical fractionation mode was used, the total focal doses were 60–66 Gy. Cisplatin was prescribed at 30 mg/m2 per week up to a total dose (SD) of 200 mg, the COX-2 inhibitor Rancelex® at a dose of 100 mg per day (active substance – celecoxib). The levels of VEGF, COX-2, and PGE-2 in the blood serum of patients with NSCLC were determined by enzyme-linked immunosorbent assay (ELISA) before and after treatment. Results. The level of the angiogenesis marker VEGF after treatment in the group with RT decreases by 1.46 times, in the group with the combined action of RT and ranselex – 2.4 times, in the group with the combined action of PT, ranselex and cisplatin – by 3.7 times, and in the group with the combined effect of RT and cisplatin, it decreases by 1.1 times. The greatest decrease in the level of VEGF is observed with RT in combination with ranselex and cisplatin, which indicates a more effective enhancement of the antiangiogenic effect. Conclusions. It has been proven that with various schemes of RT using the COX-2 inhibitor – ranselex and cisplatin in patients with NSCLC, there is a decrease in the radioresistance markers PGE-2 and COX-2, the angiogenesis marker – VEGF, which indicates that the effect of radiomodification on the angiogenesis process is most pronounced in the combined actions of RT and both radio modifiers. The use of COX-2 inhibitors as radiosensitizers in combination with RT provides a new opportunity to increase tumor radiosensitivity.

25 June 2020 in Український радіологічний та онкологічний журнал
Verified
Journal Article
Open access
PDF file
NBN. V. Bilozor
N. V. Bilozor
ВСВ. П. Старенький
В. П. Старенький
NMN. A. Mitryayeva
N. A. Mitryayeva
LGL. V. Grebinyk
L. V. Grebinyk
Background. COX-2 inhibitors facilitate disruption of the production of angiogenic factors, the use of which in combination with RT leads to a significant delay in tumor growth in experimental models of cancer. Purpose. Evaluation of the effectiveness of RT in combination with COX-2 inhibitor in patients with NSCLC (non-small-cell lung carcinoma). Materials and methods. The study involved 38 patients with NSCLC divided into 2 subgroups: Subgroup 1 was represented by 20 patients who received a RT course and celecoxib 100 mg/d, Subgroup 2 enrolled 18 patients who received only RT. The subgroups were comparable by sex, age, tumor location, general condition. Squamous cell carcinoma was detected in 19 (95.0%) patients of Subgroup 1 and in 9 (50%) patients of Subgroup 2. Stages I – II were diagnosed 4.4 times more frequently in Subgroup 2, stage III was 1.9 times more frequently detected in Subgroup 1 (p < 0.05). VEGF, COX-2 content was assessed before/after the RT course by means of a sandwich immunoassay (ELISA). Results. A positive effect (partial regression, stabilization) was observed equally in the subgroups: 80.0% and 77.8%. In Subgroup 1, partial regression was 5 times more frequent, the overall annual and recurrence-free survival increased by 15 and 29%, respectively. In patients of Subgroup 1, COX-2 was 2.4-fold decreased, in patients of Subgroup 2, COX-2 almost did not change. COX-2 blocking was accompanied by decreased VEGF: 1.9-fold in Subgroup 1, 1.4-fold in Subgroup 2. Changes in COX-2 and VEGF levels were consistent with the objective response after RT with celecoxib: in case of a positive effect, COX-2 level was significantly decreasing (2.3-1.9-fold), VEGF level was significantly decreasing (2.3–1.7-fold); progressive tumor growth was combined with a minor decrease in COX-2 and VEGF (1.5–1.4-fold). Conclusions. Radiation therapy in combination with COX-2 inhibitor enhances the effectiveness of treatment by increasing partial regressions and relapse-free survival. An objective response correlates with COX-2 and VEGF levels, which makes it possible to use them to assess RT effectiveness and decide on further treatment strategy.

1 July 2021 in Zaporozhye Medical Journal
Verified
Journal Article
Open access
PDF file
OBO. M. Bilyi
O. M. Bilyi
NMN. A. Mitriaieva
N. A. Mitriaieva
MKM. V. Krasnoselskyi
M. V. Krasnoselskyi
LHL. V. Hrebinyk
L. V. Hrebinyk
НКН. В. Красносельский
Н. В. Красносельский
Secondary edematous breast cancer (SEBC), T4b, has a poor prognosis. The aim of this study is to examine the balance in serum levels of pro-inflammatory (TNFά, IL-8) and anti-inflammatory (IL-4) cytokines in patients with SEBC before special treatment. Materials and methods. A total of 87 patients with breast cancer (BC) were examined before treatment: 42 patients with SEBC in T4bN0-3M0 stage and 45 BC patients in T3-4N1-3M0 stage without edema. The control group consisted of 15 patients with fibroadenomas. The serum levels of cytokines (IL-4, IL-8, TNFά) in the patients was determined using the enzyme-linked immunosorbent assay. Results. In the SEBC patients as compared to the patients without cancer, the serum pro-inflammatory cytokine (IL-8, TNFά) levels were significantly increased and the anti-inflammatory cytokine (IL-4) level was slightly increased in 22 %. In BC without edema, an imbalance was noted in favor of pro-inflammatory cytokines, but in SEBC it was more pronounced (31.6 versus 12.4 and 5.6 versus 3.2, respectively). Conclusions. In the majority of SEBC patients, there is an imbalance in the cytokine profile in favor of the pro-inflammatory cytokines (IL-8, TNFά). SEBC patients with elevated levels of both pro- and anti-inflammatory cytokines before treatment are the highest risk group of tumor progression and metastasis. Inhibition of the IL-8 effects or related CXC chemokines, TNFά, and others may have important consequences for the systemic treatment of SEBC.